Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$966 Mln
Revenue (TTM)
$292 Mln
Net Profit (TTM)
$0 Mln
ROE
-6.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
70.6
Industry P/E
--
EV/EBITDA
26.3
Div. Yield
0 %
Debt to Equity
2.8
Book Value
$0.1
EPS
$0
Face value
--
Shares outstanding
172,431,290
CFO
$-528.57 Mln
EBITDA
$-513.88 Mln
Net Profit
$-596.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
| -23.1 | -1.3 | -23.1 | 18.9 | 54.7 | 6.0 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
| 131.6 | 43.8 | 76.7 | -54.6 | -40.4 | -30.2 | -58.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Xeris Biopharma Holdings (XERS)
|
6.0 | 965.6 | 291.9 | 0.6 | 7.7 | -7 | -- | 70.6 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for... the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Address: 1375 West Fulton Street, Chicago, IL, United States, 60607 Read more
Chairman & CEO
Mr. Paul R. Edick
Chairman & CEO
Mr. Paul R. Edick
Headquarters
Chicago, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Xeris Biopharma Holdings Inc (XERS) is $6.04 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Xeris Biopharma Holdings Inc (XERS) has given a return of 54.74% in the last 3 years.
Since, TTM earnings of Xeris Biopharma Holdings Inc (XERS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
2,551.56
|
103.26
|
|
2024
|
-9.22
|
-17.07
|
|
2023
|
-5.21
|
-47.86
|
|
2022
|
-1.91
|
4.00
|
|
2021
|
-2.91
|
3.75
|
The 52-week high and low of Xeris Biopharma Holdings Inc (XERS) are Rs 10.08 and Rs 3.81 as of 05-Apr-2026.
Xeris Biopharma Holdings Inc (XERS) has a market capitalisation of $ 966 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Xeris Biopharma Holdings Inc (XERS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.